COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 4.05M | -10.36M | -14.91M | -18.84M | -17.56M |
| Total Depreciation and Amortization | 1.20M | 1.19M | 1.29M | 1.48M | 1.57M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -11.57M | 405.00K | 3.01M | 4.72M | 2.17M |
| Change in Net Operating Assets | -2.45M | 292.00K | 607.00K | -4.47M | -226.00K |
| Cash from Operations | -8.77M | -8.47M | -10.00M | -17.11M | -14.05M |
| Capital Expenditure | -97.00K | -710.00K | -973.00K | -1.10M | -1.21M |
| Sale of Property, Plant, and Equipment | 253.00K | 248.00K | 9.00K | 5.00K | 4.00K |
| Cash Acquisitions | -- | -- | 0.00 | 0.00 | 26.04M |
| Divestitures | -30.00K | -- | -- | -- | -- |
| Other Investing Activities | 8.00K | 4.00K | -11.00K | 203.00K | 203.00K |
| Cash from Investing | 134.00K | -458.00K | -975.00K | -896.00K | 25.03M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -247.00K | -365.00K | -459.00K | -488.00K | -549.00K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -42.00K | -42.00K | -135.00K | -209.00K | -167.00K |
| Cash from Financing | -289.00K | -407.00K | -594.00K | -697.00K | -716.00K |
| Foreign Exchange rate Adjustments | 172.00K | 252.00K | 97.00K | 227.00K | -17.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -8.75M | -9.09M | -11.47M | -18.47M | 10.25M |